Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › emtricitabine

emtricitabine

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of emtricitabine

12 trials tracked of emtricitabine: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 13 citations.

12Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 5 Other / NA 2
  1. Phase 4 The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age Completed · 13 cited
  2. Phase 4 Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women Completed
  3. Phase 4 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed
  4. Phase 3 A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment Completed
  5. Phase 3 NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission Completed
  6. Phase 2 A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years Completed
Show 6 more trials
  1. Phase 2 Study to Evaluate a HIV Drug for the Treatment of HIV Infection Completed
  2. Phase 2 Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen Completed
  3. Phase 2 Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine Completed
  4. Phase 2 Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women Completed
  5. N/A Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults Completed
  6. N/A Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CDC updates recommendations for HIV nonoccupational postexposure prophylaxis
Infectious Disease
CDC updates recommendations for HIV nonoccupational postexposure prophylaxis CDC updates recommendations for HIV prevention medication after possible exposure
The CDC has issued updated recommendations for antiretroviral postexposure prophylaxis following nonoccupational HIV exposure.
The CDC updated its guidance on taking HIV prevention medication after a possible exposure to help doctors give the most current advice.
CDC Apr 4, 2026
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Allergy & Immunology Phase III
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1 Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
CT.gov Apr 2, 2026